

# Group B Streptococcus (GBS) Market 2026

<https://marketpublishers.com/r/G22211EEC74AEN.html>

Date: December 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: G22211EEC74AEN

## Abstracts

The Group B Streptococcus (GBS) Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Group B Streptococcus (GBS) Market.

This report delivers a comprehensive overview of the Group B Streptococcus (GBS) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Group B Streptococcus (GBS) Market. The Group B Streptococcus (GBS) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Group B Streptococcus (GBS) Market Scope:

By Infection Type

Bacteremia

Meningitis

Sepsis

Pneumonia

Bone and joint infections

Skin and soft tissue infections

Urinary tract infections

#### By Treatment

Antibiotics

Surgery

#### By End User

Hospitals

Homecare

Specialty Clinics

Others

#### Key Players

Pfizer Inc

MinervaXApS

Wellstat Vaccines LLC

GlaxoSmithKline

LUMINEX CORPORATION

PATH

USAntibiotics

Novartis

HAL

TAJ LIFE SCIENCES PVT. LTD

## Major Highlights

This report delivers a comprehensive overview of the Group B Streptococcus (GBS) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Group B Streptococcus (GBS) Market. The Group B Streptococcus (GBS) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

### Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Infection Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by End User
- 3.4. Snippet by Region

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. The rising prevalence of Group B Streptococcus
    - 4.1.1.2. The rising the clinical trials on Group B Streptococcus
- 4.2. Restraints
  - 4.2.1.1. Side effects associated with the treatment
  - 4.2.2. Opportunity
    - 4.2.2.1. A significant chance exists for developing a GBS vaccination
  - 4.2.3. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of COVID-19
  - 6.1.1. Scenario Before COVID
  - 6.1.2. Scenario During COVID
  - 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

## **7. BY INFECTION TYPE**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  - 7.1.2. Market Attractiveness Index, By Infection Type
- 7.2. Bacteremia \*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Meningitis
- 7.4. Sepsis
- 7.5. Pneumonia
- 7.6. Bone and joint infections
- 7.7. Skin and soft tissue infections
- 7.8. Urinary tract infections

## **8. BY TREATMENT**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  - 8.1.2. Market Attractiveness Index, By Treatment
- 8.2. Antibiotics \*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Surgery

## **9. BY END USER**

- 9.1. Introduction
  - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

- 9.1.2. Market Attractiveness Index, By End User
- 9.2. Hospitals\*
  - 9.2.1. Introduction
  - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Homecare
- 9.4. Specialty Clinics
- 9.5. Others

## **10. BY REGION**

- 10.1. Introduction
  - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
  - 10.2.1. Introduction
  - 10.2.2. Key Region-Specific Dynamics
  - 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  - 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  - 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    - 10.2.5.1. U.S.
    - 10.2.5.2. Canada
    - 10.2.5.3. Mexico
- 10.3. Europe
  - 10.3.1. Introduction
  - 10.3.2. Key Region-Specific Dynamics
  - 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  - 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  - 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  - 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 10.3.7.1. Germany
    - 10.3.7.2. UK
    - 10.3.7.3. France
    - 10.3.7.4. Italy
    - 10.3.7.5. Spain
    - 10.3.7.6. Rest of Europe
- 10.4. South America
  - 10.4.1. Introduction
  - 10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.6.1. Brazil

10.4.6.2. Argentina

10.4.6.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.6.1. China

10.5.6.2. India

10.5.6.3. Japan

10.5.6.4. Australia

10.5.6.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

## **11. COMPETITIVE LANDSCAPE**

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

## **12. COMPANY PROFILES**

12.1. Pfizer Inc\*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Financial Overview

12.1.4. Key Developments

- 12.2. MinervaXApS
- 12.3. Wellstat Vaccines LLC
- 12.4. GlaxoSmithKline
- 12.5. LUMINEX CORPORATION
- 12.6. PATH
- 12.7. USAntibiotics
- 12.8. Novartis
- 12.9. HAL
- 12.10. TAJ LIFE SCIENCES PVT. LTD (\*LIST NOT EXHAUSTIVE)

### **13. APPENDIX**

- 13.1. About Us and Services
- 13.2. Contact Us

## I would like to order

Product name: Group B Streptococcus (GBS) Market 2026

Product link: <https://marketpublishers.com/r/G22211EEC74AEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G22211EEC74AEN.html>